期刊文献+

加巴喷丁联合普拉克索治疗不宁腿综合征的临床研究 被引量:6

Clinical observation of gabapentin combined with pramipexole in the treatment of restless legs syndrome
下载PDF
导出
摘要 目的观察加巴喷丁联合普拉克索治疗不宁腿综合征的临床效果,为临床治疗此类疾病提供一种可行的治疗方法。方法26例诊断为RLS的患者随机分为2组:单用普拉克索治疗组(A组)和加巴喷丁联合普拉克索治疗组(B组),每组13例。A组给予普拉克索口服,最终剂量为0.25 mg/d;B组除给予相同剂量的普拉克索外,给予加巴喷丁口服,剂量为600 mg/d。均连续用药12周,记录两组患者治疗前(T_0)、治疗后2周(T_2)、6周(T_6)、12周(T_(12))的IRLS(不宁腿严重程度量表)、PSQI(匹兹堡睡眠质量指数)、AIS(阿森斯失眠量表)、VAS(疼痛视觉模拟评分),以此来评估疗效并记录两组治疗的不良反应。结果治疗后各观察时间点,两组患者IRLS、AIS、PSQI、VAS评分较治疗前均有不同程度的下降,差异有统计学意义(P<0.01)。在治疗后2周,B组各项治疗效果优于A组(P<0.05)。在治疗后6周及12周,B组在改善IRLS、PSQI上仍然明显优于A组(P<0.05)。A组、B组的药物不良反应发生率分别为23.1%(3/13)和38.5%(5/13),差异无统计学意义。A组最常见的不良反应为头痛、恶心,B组最常见的不良反应除头痛、恶心外,还有头晕、口干。结论加巴喷丁联合普拉克索治疗不宁腿综合征的临床疗效较单用普拉克索疗效好,且安全性较高,耐受性较好,未见严重不良反应的发生。 Objective To observe the clinical effect of gabapentin and pramipexole orally taken on patients with restless legs syndrome,in order to provide a feasible treatment method for this kind of disease.Methods 26 patients with restless legs syndrome were divided into two groups randomly.Group A was treated with pramipexole and group B was orally administered gabapentin and pramipexole,13 cases in each group.The dosage of pramipexole in patients of two groups were both 0.25 mg daily.In addition,g roup B was given gabapentin 600 mg once a day orally before sleep.The periods of treatment were both 12 weeks.The IRLS(International Restless Legs Syndrome Study Group rating scale),PSQI(Pittsburgh Sleep Quality Index),AIS(Athens Insomnia Scale)and VAS(Visual Analogue Scale/Score)were recorded before treatment(T_0)and at 2 weeks(T_2),6weeks(T_6),12 weeks(T_(12))after treatment,in order to evaluate the clinical effect.The adverse reactions in the course of treatment were both recorded.Results The IRLS,PSQI,AIS and VAS scores of the two groups decreased at T_2,T_6 and T_(12)(P〈0.01).The clinical efficacy of group B was statistically different from group A at T_2 in IRLS,PSQI,AIS and VAS scores(P〈0.05).There were significant differences between the two groups in IRLS and PSQI at T_6 and T_(12).The incidence of adverse drug reactions was 23.1%(3/13)and 38.5%(5/13),respectively.No significant difference of overall adverse reactions existed.The most common adverse reactions of group A included headache and nausea,while dizziness and dry mouth were the common adverse reactions of group B besides headache and nausea.Conclusion The combination of gabapentin with pramipexole is effective and safe for the patients with restless legs syndrome.
出处 《实用药物与临床》 CAS 2016年第4期421-425,共5页 Practical Pharmacy and Clinical Remedies
基金 国家自然科学基金资助项目(81271371)
关键词 不宁腿综合征 加巴喷丁 普拉克索 Restless legs syndrome Gabapentin Pramipexole
  • 相关文献

参考文献27

  • 1Ekbom A. Restless legs:a clinical study [ J]. Acta Med Scand, 1945,158(suppl) :1-123.
  • 2Ohayon MM, O'Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature [ J ]. Sleep Meal Rev,2012,16(4) :283-295.
  • 3Ma JF,Xin XY,Liang L,et al. Restless legs syndrome in Chi- nese elderly people of an urban suburb in Shanghai : a comrnu- nity-basedsurvey [J]. Parkinsonism Relat Disord, 2012, 18 (3) :294-298.
  • 4王维冶主编.神经病学[M].北京:人民卫生出版社,2006:1 23 8-1240
  • 5Silver N,Allen RP, Senerth J, et al. A lO-year, longitudinal as- sessment of dopamine agonists and methadone in the treatment of restless legs syndrome [ J ]. Sleep Med, 2011,12 ( 5 ) : 440- 444.
  • 6Fulda S, Wetter TC. Dopamine agonists for the treatment of restless legs syndromel J]. Expert Opin Pharmacother,2005,6 (15) :2655-2666.
  • 7Allen RP, Picchietti D, Hening WA, et al. Restless legs syn- drome : diagnostic criteria, special considerations, and epidemi- ology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health [J]. Sleep Med,2003,4(2) :101-119.
  • 8Hening WA. Current guidelines and standards of practice for restless legs syndrome [ J ]. Am J Med ,2007,120 ( 1 S uppl 1 ) : S22-S27.
  • 9Garcia-Borreguero D, Williams AM. An update on restless legs syndrome ( Willis-Ekbom disease) : clinical features, pathogen- esis and treatment [J]. Curr Opin Neurol, 2014,27 ( 4 ) : 493- 501.
  • 10Waiters AS, LeBrocq C, Dhar A, et al. Validation of the Inter- national Restless Legs Syndrome Study Group rating scale for restless legs syndrome [J]. Sleep Med, 2003,4 : 121 -132.

二级参考文献99

  • 1冯国双,陈景武,杨秀珍.某医学院校学生睡眠质量调查及其影响因素分析[J].中华流行病学杂志,2005,26(5):328-331. 被引量:78
  • 2Partinen M, Hirvonen K, Jama L, et al. Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study)[J]. Sleep Med, 2008, 9(5): 537-541.
  • 3Gamaldo CE, Earley CJ. Restless legs syndrome: a clinical update [J]. Chest, 2006, 130(5): 1596-1604.
  • 4Brindani F, Vitetta F, Gemignani F. Restless legs syndrome: differential diagnosis and management with pramipexole [J]. Clin Interv Aging, 2009, 4: 305-313.
  • 5Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health[J]. Sleep Med, 2003, 4(2): 101-119.
  • 6Yee B, Killick R, Wong K. Restless legs syndrome[J]. Aust Faro Physician, 2009, 38(5): 296-300.
  • 7Earley C J, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome [J]. Neurology, 2000, 54(8): 1698-1700.
  • 8Manconi M, Govoni V, De Vito A, et al. Restless legs syndrome and pregnancy[J]. Neurology, 2004, 63(6): 1065-1069.
  • 9Winkelman JW, Chertow GM, Lazarus JM. Restless legs syndrome in end-stage renal disease [J]. Am J Kidney Dis, 1996, 28(3): 372-328.
  • 10Merlino G, Fratticci L, Valente M, et al. Association of restless legs syndrome in type 2 diabetes: a case-control study[J]. Sleep, 2007, 30(7): 866-871.

共引文献51

同被引文献118

引证文献6

二级引证文献34

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部